← Back to patent-cliff list
盐酸氨溴索
Tier C — Watch / tradeAmbroxol Hydrochloride
勃林格殷格翰
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：SCNA
Brand：必与、沐舒坦、奥古丽、贝莱、乐舒凡、Lasolvan、抒坦清、百沫舒、Mucosolvan、兰苏、Lazolvan、Ponophen、Mucoangin、伊诺舒、平坦、坦静、安普索、Mucosal-L、Mucosolvan-L、双倡
Indications (approved)：麻醉、咽炎、呼吸道疾病、支气管炎
Regional status
US
无进展
2012-12-01
EU
批准上市
2001-07-11
China
批准上市
1998-01-01
Japan
批准上市
1984-03-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ambroxol Hydrochloride?
Approved indications include: 麻醉, 咽炎, 呼吸道疾病, 支气管炎.
When does the Ambroxol Hydrochloride patent expire?
No public expiry year is available for Ambroxol Hydrochloride yet; this page updates once verified.
How do I get a quote for Ambroxol Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25